<unk> , sold under the brand names Vonvendi and Veyvondi, is a medicine used to control bleeding in adults with von Willebrand disease (an inherited bleeding disorder). It is a recombinant von Willebrand factor. The most common adverse reactions are generalized itching, vomiting, nausea, dizziness, and vertigo.<unk>  should not be used in the treatment of Hemophilia A. In the UK it is available only via a named patient access program.<unk>  was approved for medical use in the United States in December 2015, in the European Union in August 2018, and in Australia in April 2020. It was granted orphan drug designations in both the United States and the European Union.
Vonicog alfa
Efmoroctocog alfa
Drotrecogin alfa
Susoctocog alfa
Damoctocog alfa pegol
Etelcalcetide
Turoctocog alfa
Moroctocog alfa